SKIN - Bragar Eagel & Squire P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Acelyrin and Beauty Health and Encourages Investors to Contact the Firm | Benzinga
NEW YORK, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Acelyrin, Inc. (NASDAQ:SLRN), and Beauty Health Company (NASDAQ:SKIN). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Acelyrin, Inc. (NASDAQ:SLRN)
Class Period: May 4, 2023 - September 11, 2023
Lead Plaintiff Deadline: January 16, 2024
According to the filed complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) izokibep was less effective in treating HS than Defendants had led investors to believe; (ii) accordingly, Acelyrin overstated izokibep's clinical and/or commercial prospects; (iii) as a result, Acelyrin also overstated the Company's business prospects post-IPO; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
For more information on the Acelyrin class action go to: https://bespc.com/cases/SLRN
Beauty Health Company (NASDAQ:SKIN)
Class Period: May 10, 2022 - ...